Welcome to Thrombosis and Haemostasis

(1) Department of Internal Medicine and Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, the Netherlands; (2) Maastricht Anticoagulation Clinic, Maastricht, the Netherlands

(1) Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy

(1) Atherothrombosis & Vascular Biology, Baker IDI Heart & Diabetes Institute, Melbourne, Australia

(1) Division of Cardiovascular Sciences, Laboratory of Thrombosis and Haemostasis, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain

(1) Department of Hematology, Division of Hemostasis and Thrombosis, University Medical Center Groningen, Groningen, the Netherlands

(1) Departments of Thrombosis and Haemostasis, Leiden University Medical Center, Leiden, The Netherlands; (2) University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK; (3) Department of Neurology, University Hospital Essen, Essen, Germany; (4) Global Clinical Development and Medical Affairs, Boehringer Ingelheim GmbH & Co. KG, Ingelheim, Germany; (5) Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany

(1) Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany; (2) Institute for Medical Biometry, Informatics and Epidemiology, University Clinic Bonn, Bonn, Germany; (3) Life and Medical Sciences Institute, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany

(1) Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; (2) Department of Haematology, Auckland City Hospital, Auckland, New Zealand; (3) School of Biological Sciences, University of Auckland, Auckland, New Zealand; (4) Australian Centre for Blood Diseases, Monash University, Melbourne, Australia; (5) Lab Plus, Auckland City Hospital, Auckland, New Zealand; (6) Department of Haematology, Palmerston North Hospital, Palmerston North, New Zealand

(1) Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada

(1) Department of Laboratory Medicine, Soon Chun Hyang University Hospital, Seoul, Republic of Korea; (2) Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; (3) Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; (4) Cardiovascular Product Evaluation Center, Yonsei University Health System, Seoul, Republic of Korea

(1) Cardiovascular Research, Physiology Institute, University of Zurich, Zurich, Switzerland; (2) Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland; (3) Cardiology, Cardiovascular Center, University Hospital Zurich, Zurich, Switzerland; (4) Vascular Biology, Department of Medicine, University of Fribourg, Fribourg, Switzerland

(1) Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany; (2) Department of Internal Medicine II - Cardiology, University of Ulm Medical Center, Ulm, Germany; (3) Department of Statistics, Ludwig-Maximilians-Universität München, Munich, Germany

(1) Laboratório de Tecido Conjuntivo, Hospital Universitário Clementino Fraga Filho and Programa de Glicobiologia, Instituto de Bioquímica Médica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

(1) Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb, Plainsboro, New Jersey, USA; (2) Exploratory Development Global Biometric Sciences, Bristol-Myers Squibb, Princeton, New Jersey, USA; (3) Analytical and Bioanalytical Department, Bristol-Myers Squibb, Princeton, New Jersey, USA; (4) Global Medical Affairs, Bristol-Myers Squibb, Princeton, New Jersey, USA

(1) Daiichi Sankyo Pharma Development, Edison, New Jersey, USA; (2) Pharsight Corporation, Sunnyvale, California, USA; (3) TIMI Study Group Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; (4) Daiichi Sankyo Company, Ltd., Tokyo, Japan; (5) Daiichi Sankyo India Pharma Private Ltd, Mumbai, India

(1) State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, People’s Republic of China; (2) Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming, PR China

(1) Center for Biomedical Research, The University of Texas Health Science Center at Tyler, Tyler, Texas, USA; (2) Department of Medicine, Malmö University Hospital, University of Lund, Malmö, Sweden; (3) Coagulation Biology Laboratory, Oklahoma Medical Research Foundation, Howard Hughes Medical Institute, Oklahoma City, Oklahoma, USA

(1) University Paris Diderot, Sorbonne Paris Cité, Inserm UMR698, Paris, France; (2) AP-HP Hospital Bichat Claude Bernard, Paris, France

(1) Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada; (2) Canadian Blood Services, Research and Development, Hamilton, Ontario, Canada

(1) Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for LIfe Sciences (NARILIS), University of Namur, Belgium; (2) Hematology Laboratory, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for LIfe Sciences (NARILIS), CHU Mont-Godinne, Université Catholique de Louvain, Belgium; (3) Hematology Department, Namur Thrombosis and Hemostasis Center, CHU Mont-Godinne, Université Catholique de Louvain, Belgium